Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
PR Newswire•06/10/2026•09:00 ET
0
Key Highlights
- ➤Co-Diagnostics (CODX) will showcase its Co-Dx PCR platform and MTB test in Johannesburg.
- ➤Ebola assay development continues, with sensitivity optimization for decentralized Co-Dx PCR testing.
- ➤U.S. Ebola response funding reached approximately $887 million after an additional $267 million allocation.
- ➤Co-Dx PCR platform and associated tests remain unavailable for sale pending FDA and other regulatory review.
- ➤Co-Diagnostics is pursuing grants and other funding to advance its Ebola assay development.
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development PR Newswire
Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform
Get started
Create a free account to read the full story.